Overcome the challenges of insufficient material, poor sensitivity and false positives by analyzing DNA, RNA, and identifying somatic CHIP mutations.
Accelerate enrollment by identifying biomarker+ patients from our extensive network of clinical sites, supported by dedicated clinical trial nurse navigators.
MI Trials offers patients and physicians access to the latest drugs being developed to improve clinical outcomes. According to National Cancer Institute statistics, awareness of available trials is low and overall participation in oncology trials is less than five percent. Caris helps increase awareness and participation of clinical trials through Caris Trial Solutions.
Access a dedicated cross-functional team to address questions and enhance programs by leveraging Caris’ clinico-genomic database of more than 482K matched profiles.
Caris has amassed a longitudinal multiomic data library that spans over 482k+ patients across 55+ indications. Biopsies come to Caris for sequencing across the standard of care. Our partners can interrogate the data to understand the tumor biology within the context of clinical care. Caris RWD is an unmatched resource for discovery and clinical development programs.